Servicio de Neurología, Hospital Clínico San Carlos, Madrid 28040, Spain.
J Neurol Sci. 2011 Dec 15;311(1-2):98-102. doi: 10.1016/j.jns.2011.09.001. Epub 2011 Oct 1.
Although the etiology of multiple sclerosis (MS) is unknown, it is generally believed that genetic, immunologic, and environmental factors are involved. The objectives of this study were: 1. to analyze if a genetic control could explain why HHV-6 would be able to actively replicate in a subset of MS patients but not in controls; 2. to study if MS patients with HHV-6 active replication are clinically different from those without HHV-6 active replication. A total of 195 MS patients and 195 controls were analyzed for two SNPs at the MHC2TA locus and two SNPs at the CD46 locus. Furthermore, the MS cohort was analyzed by PCR for the detection of HHV-6 genomes in five serum samples collected every six months along two-year follow-up. We found that 59/195 (30.2%) MS patients had at least one HHV-6 positive serum sample. No statistical significant difference was found for the two genes when the comparison was made between MS patients and controls; however, a statistical significance was found for the two polymorphisms of MHC2TA when we compared MS patients with active replication and controls (p=0.0000004 for rs4774C and p=0.011 for rs3087456G). Furthermore, increased significant differences were found for MHC2TA and CD46 when we compared interferon beta responders and non-responders within MS patients. In conclusion, we describe a gene-environment interaction in MS patients between HHV-6 and MHC2TA and CD46 that should be further studied to clarify if that interaction could be a genetic control. The results show that MS patients without HHV-6 active replication are better responders to interferon beta treatment than those with HHV-6 active replication.
虽然多发性硬化症(MS)的病因不明,但普遍认为遗传、免疫和环境因素都有参与。本研究的目的是:1. 分析遗传控制是否可以解释为什么 HHV-6 能够在一部分 MS 患者中而不是在对照组中积极复制;2. 研究是否 MS 患者中 HHV-6 积极复制与无 HHV-6 积极复制的患者在临床上存在差异。共对 195 例 MS 患者和 195 名对照者进行了 MHC2TA 基因座上的两个 SNP 和 CD46 基因座上的两个 SNP 的分析。此外,对 MS 队列进行了 PCR 分析,以检测在两年随访期间每六个月采集的五份血清样本中的 HHV-6 基因组。我们发现,195 例 MS 患者中有 59 例(30.2%)至少有一份血清样本呈 HHV-6 阳性。MS 患者与对照组相比,这两个基因无统计学显著差异;然而,当我们比较有 HHV-6 积极复制的 MS 患者和对照组时,MHC2TA 的两个多态性有统计学显著差异(rs4774C 的 p=0.0000004,rs3087456G 的 p=0.011)。此外,当我们比较 MS 患者中的干扰素β应答者和非应答者时,MHC2TA 和 CD46 存在显著差异。总之,我们描述了 MS 患者中 HHV-6 与 MHC2TA 和 CD46 之间的基因-环境相互作用,需要进一步研究以阐明这种相互作用是否是一种遗传控制。结果表明,无 HHV-6 积极复制的 MS 患者对干扰素β治疗的反应优于有 HHV-6 积极复制的患者。